ARMP
Armata Pharmaceuticals, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q3 2026: 8 added (0 new), 4 trimmed or exited.
- AnalystsBULLISH
7 of 8 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.570 → −$0.510 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +1.4% to 912.6K shares. 9.8 days to cover, ≈2.5% of shares.
- TrendRANGE
20% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| STATE STREET CORP | ADD | $677.1K |
| UBS Group AG | DOUBLED | $199.6K |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $127.2K |
| BARCLAYS PLC | ADD | $18.8K |
| Russell Investments Group, Ltd. | DOUBLED | $16.5K |
| FMR LLC | DOUBLED | $5.2K |
| CITIGROUP INC | NEAR_EXIT | $2.2K |
| SIMPLEX TRADING, LLC | NEAR_EXIT | $671.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
8 analystsPrice is below the lowest target. Median implies +485%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 23, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Birx Deborah Chief Executive Officer Jul 10, 2026 | TAX W/H | $59.8K |
Gilmer Daniel B. Director Apr 24, 2026 | AWARD | 51,280 sh |
Kyme Pierre Chief Business Officer Mar 14, 2026 | TAX W/H | $10.9K |
Birx Deborah Chief Executive Officer Mar 14, 2026 | TAX W/H | $51.8K |
Schlesinger Sarah J. Director Mar 9, 2026 | AWARD | 25,640 sh |
Kyme Pierre Chief Business Officer Mar 9, 2026 | AWARD | 183,142 sh |
Odysseas Kostas D Director Mar 9, 2026 | AWARD | 25,640 sh |
PATTI JOSEPH M Director Mar 9, 2026 | AWARD | 25,640 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.51 | -$0.51–-$0.51 | -27.5% | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | -$1.46 | -$1.46–-$1.46 | +21.7% | $3.3M |
| Next FY | -$1.39 | -$1.92–-$0.85 | +4.2% | $2.8M |
Short side
FINRA· Oct 30, 2026SecBot reports
6 filings · 3 bullish · 1 bearish · 2 neutral- NEUTRAL PRESS-RELEASENov 12, 2026
Armata Pharmaceuticals reported Q3 2026 GAAP net income of $54.9M ($1.15 basic EPS, $(0.24)…
The Phase 3 start timing for AP-SA02 is the key catalyst; monitor FDA protocol concurrence and any further non-dilutive funding announcements. The convertible loan fair value gain is non-recurring…
- BULLISH 8-KSep 23, 2026
Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S…
The DoW's first Phase 3-specific funding tranche validates the AP-SA02 program's regulatory and clinical progress. Monitor for additional DoW funding commitments and Phase 3 trial initiation in H2…
- BULLISH 8-KSep 14, 2026
Armata Pharmaceuticals announced FDA Breakthrough Therapy designation for AP-SA02, its intravenous…
This Breakthrough Therapy designation is a major derisking event for AP-SA02, providing expedited FDA review and enhanced regulatory engagement. The strong Phase 2 efficacy data (100% vs 75%…
- BULLISH 8-KJul 20, 2026
Armata Pharmaceuticals announced clinical, regulatory, and manufacturing progress for its lead…
The clinical progress is a positive step but the real catalyst will be the initiation of the Phase 3 study and eventual data readout. Monitor for Phase 3 start in H2 2026 and any additional funding…
All ARMP filing & press-release reports (6)
- PRESS-RELEASE reportNov 12, 2026
- 8-K reportSep 23, 2026
- 8-K reportSep 14, 2026
- 8-K reportJul 20, 2026
- 8-K reportMay 13, 2026
- 8-K reportApr 27, 2026